Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $173.8652W HIGH $338.71
Volume
70.21 K
Value Traded
43.51 M
Short % Float
13.17%
Days to Cover
8.7
-1.91%Week
-1.77%1 Month
+14.36%3 Month
+52.2%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.26 B
EPS (TTM)
9.33
P/E Ratio
31.25
Ent. Value
2.37 B
Total Shares
7.75 M
Float Shares
7.45 M
Insiders
3.82%
Institutions
120.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
UFPT Catalyst Timeline
Dated clinical, regulatory and corporate events for UFP Technologies Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for UFP Technologies Inc
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How UFPT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
UFP Technologies Inc is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every UFPT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KOZIN MARC DDirector | Sell | -3,650 24,462 held | $303.97 | 08/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in UFPT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in UFPT for Q2 2026. | ||||
UFPT Institutional Ownership Trends
UFPT Short Interest
Shares sold short, counted twice a month.
13.17%
Short % of Float
of tradable shares sold short
981.0K
Shares Sold Short
-5.4% vs prior count
8.7 High
Days to Cover
trading days of normal volume to buy every short share back
112.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How UFPT ranks across every disease it competes in
Competitive Position is a premium feature
See how UFPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialUFPT News
-UFPT
Oct 29, 2026▲ +1.9%today
UFP Technologies to Report Third Quarter 2026 Financial Results on November 3, 2026
UFP Technologies, Inc. announced it will report its third quarter financial results on November 3, 2026, after market close. A conference call to discuss these results is scheduled for November 4. The company focuses on contract development and manufacturing for medical devices and custom products.
Read more →-UFPT
Aug 20, 2026UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the 17th Annual Midwest IDEAS Investor Conference on August 26th in Chicago, IL
UFP Technologies, Inc. will present at the 17th Annual Midwest IDEAS Investor Conference on August 26, 2026. CEO Mitchell Rock and CFO Ron Lataille will host one-on-one meetings and deliver a presentation starting at 8:35 AM CT. The event will take place at The InterContinental in Chicago, IL, and the presentation will be available via webcast.
Read more →-UFPT
Aug 3, 2026▲ +25.2%on this news
UFP Technologies Announces Record Q2 Results
UFP Technologies, Inc. reported impressive financial results for Q2 2026, achieving a net income of $20.9 million, which represents a 21.4% increase from the previous year. The company's net sales also rose by 15.1%, reaching $174.0 million. These results highlight the company's strong performance in the medical device and packaging sectors.
Read more →-UFPT
Jul 29, 2026UFP Technologies to Report Second Quarter 2026 Financial Results on August 3, 2026
UFP Technologies, Inc. plans to report its second quarter financial results on August 3, 2026, after the market closes. Following this, a conference call is scheduled for August 4, 2026, to discuss the results. The company specializes in medical device solutions and sterile packaging.
Read more →-UFPT
Jul 1, 2026UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer Conference
UFP Technologies, Inc. is set to present and conduct one-on-one investor meetings at the CJS Securities 26th Annual New Ideas Summer Conference. This event provides a platform for the company to engage with potential investors and discuss its business strategies and innovations. The conference is an opportunity for UFP to showcase its market position and future prospects.
Read more →-UFPT
Jun 4, 2026UFP Technologies Names Ryan Stafford General Counsel and Senior Vice President of Human Resources
UFP Technologies has announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeds Chris Litterio, who is retiring after contributing significantly to the company's growth. With extensive experience in legal and HR leadership from high-growth public companies, Stafford aims to support UFP's continued expansion through strategic acquisitions and organizational development. CEO Mitch Rock expressed enthusiasm for Stafford's joining the team, highlighting his expertise and strategic perspective as key assets for the company.
Read more →-UFPT
May 4, 2026UFP Technologies Announces Strong Q1 Results
UFP Technologies has announced its financial results for the first quarter. The report highlights the company's performance but lacks specific details regarding revenue or profit figures. The announcement indicates a stable outlook for the company moving forward. Further analysis may be required to understand the implications of these results.
Read more →-UFPT
Feb 24, 2026UFP Technologies Announces Record 2025 Results
UFP Technologies, Inc. reported record financial results for 2025, achieving a net income of $68.3 million, a 15.8% increase compared to 2024. The company saw a 19.5% rise in net sales, reaching $602.8 million, primarily driven by a 23.2% growth in medical sales. Despite these positive results, concerns about labor inefficiencies at their Illinois facility were noted, which affected gross margins. Additionally, sales in the non-medical sector decreased by 11.5%, highlighting a need for focus on that area.
Read more →-UFPT
Nov 3, 2025UFP Technologies Announces Strong Q3 2025 Results
UFP Technologies, Inc. reported strong Q3 2025 results, with net income of $16.4 million, consistent with the same quarter last year. Sales rose by 6.5% to $154.6 million, driven by a 7.3% increase in medical sales, despite a contraction in the non-medical segment. The company is progressing in its strategic initiatives, including program transfers to its new facility in the Dominican Republic and launching new robotic surgery programs. However, the impact of increased labor costs has tempered full earnings potential for the quarter.
Read more →-UFPT
Aug 21, 2025Welcome Investors March 2022 Welcome Investors August 2025
UFP Technologies, a contract development and manufacturing organization, has released forward-looking statements regarding its future financial performance and operational expectations. The company, headquartered in Newburyport, MA, specializes in single-use polymer-based medical devices and aims to navigate various market trends and growth strategies. However, these statements highlight significant risks, including potential decreases in product demand and operational challenges that could impact the company's projections.
Read more →-UFPT
Jun 10, 2025Welcome Investors March 2022 Welcome Investors June 2025
UFP Technologies, a contract development and manufacturing organization, made several forward-looking statements regarding its business prospects and market conditions. The company reported key statistics, including an annual revenue of approximately $600 million and a market cap of around $1.85 billion. UFP Technologies emphasized its expertise in medical device manufacturing while highlighting various operational risks and uncertainties that could impact its future performance, including decreased demand and reliance on major customers.
Read more →-UFPT
Aug 26, 2024Welcome Investors March 2022 Welcome Investors August 2024
UFP Technologies provided a presentation outlining its business strategy and operating performance. The focus is on leveraging high-growth areas, particularly in MedTech, where they have developed strong customer relationships and innovative manufacturing capabilities. While the company has experienced substantial growth opportunities, it also faces significant risks, including reliance on key customers and external economic conditions. There is an emphasis on strategic acquisitions to enhance their market position and operational efficiency.
Read more →-UFPT
Jun 11, 2024Welcome Investors March 2022 Welcome Investors June 2024
UFP Technologies has issued forward-looking statements regarding its financial performance and growth strategies. The company emphasizes its expertise in medical device manufacturing and highlights opportunities for acquisitions and organic growth in high-margin niches. However, it also cautions investors about various risks and uncertainties, including geopolitical issues and challenges in maintaining customer relationships. Investors are encouraged to review SEC filings for a comprehensive understanding of potential risks.
Read more →-UFPT
Nov 28, 2023Welcome Investors March 2022 Welcome Investors November 2023
UFP Technologies provided insights into their forward-looking strategies and business operations, emphasizing their focus on acquisitions and market growth. The company operates in various sectors, notably MedTech, and incorporates non-GAAP financial measures to present its performance. However, they acknowledge several risks that could affect future operations, including customer retention challenges and geopolitical influences. The company aims to expand its market presence while navigating these potential uncertainties.
Read more →-UFPT
Aug 21, 2023Welcome Investors March 2022 Welcome Investors August 2023
UFP Technologies provided an overview of its business operations, including forward-looking statements regarding its financial performance and strategic acquisitions. The company highlighted its capabilities in medical devices and packaging while cautioning investors about risks such as customer dependency and global economic conditions. Additionally, it emphasized its growth potential in niche markets and its experience in high-margin medical product development. This presentation combines both a review of current success and a focus on future opportunities and challenges.
Read more →-UFPT
Jun 13, 2023Welcome Investors March 2022 Welcome Investors June 2023
UFP Technologies has presented forward-looking statements regarding its growth strategy, emphasizing its focus on the MedTech market and the benefits of strategic acquisitions. The company aims to enhance its market presence through diverse offerings in medical devices and specialized components. However, risks associated with economic conditions and geopolitical tensions present challenges that could impact its future performance. UFP is committed to providing comprehensive solutions while navigating these uncertainties.
Read more →-UFPT
Mar 21, 2023Welcome Investors March 2022 Welcome Investors March 2023
UFP Technologies presented its forward-looking statements regarding financial and operational performance for 2022 and 2023. The company highlighted its strategic focus on acquisitions and growth in high-margin markets, particularly in MedTech, which comprises a significant portion of its revenue. However, it acknowledged various risks, including economic uncertainties and challenges in integrating acquisition candidates, accompanied by potential impacts from geopolitical tensions and supply chain issues.
Read more →-UFPT
Nov 15, 2022Welcome Investors November 16, 2022
Welcome Investors November 16, 2022 Forward Looking Statements 2 Certain statements in this presentation may be considered "forward - looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forwa
Read more →-UFPT
Sep 20, 2022Welcome Investors September 21, 2022
Welcome Investors September 21, 2022 Forward Looking Statements 2 Certain statements in this presentation may be considered "forward - looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forw
Read more →-UFPT
Jun 14, 2022Welcome Investors June 16, 2022
Welcome Investors June 16, 2022 Forward Looking Statements 2 Certain statements in this presentation may be considered "forward - looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward -
Read more →About UFP Technologies Inc
Headquarters100 HALE STREET, NEWBURYPORT, MA, 01950
BIOPHARMAWATCH ELITE PLUS
Trade the next UFPT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime